Imperial College London

Miles S Capper

Faculty of EngineeringDepartment of Earth Science & Engineering

Research Postgraduate







2.57FRoyal School of MinesSouth Kensington Campus





Publication Type

6 results found

Sullivan KV, Moore RET, Capper MS, Schilling K, Goddard K, Ion C, Layton-Matthews D, Leybourne MI, Coles B, Kreissig K, Coombes RC, Larner F, Rehkamper Met al., 2021, Zinc stable isotope analysis reveals Zn dyshomeostasis in benign tumours, breast cancer, and adjacent histologically normal tissue, Matallomics

Journal article

Schilling K, Moore RET, Sullivan KV, Capper M, Rehkamper M, Goddard K, Ion C, Coombes RC, Vesty-Edwards L, Lamb AD, Halliday AN, Larner Fet al., 2021, Zinc stable isotopes in urine as diagnostic for cancer of secretory organs, Lamont‐Doherty Earth Observatory, Columbia University, Palisades, NY, US

Journal article

Capper MS, Enriquez Garcia A, Lai B, Wang BO, Gelfand BS, Shemanko CS, Jalilehvand Fet al., 2021, The effect of sodium thiosulfate on cytotoxicity of a diimine Re(i) tricarbonyl complex, Dalton Transactions, ISSN: 1477-9226

<p>Replacing the aqua ligand in <italic>fac</italic>-[(Re(CO)<sub>3</sub>(bpy)(H<sub>2</sub>O)]<sup>+</sup> with S<sub>2</sub>O<sub>3</sub><sup>2−</sup> disrupts the cellular uptake of the product in the MD-MB-231 breast cancer cells.</p>

Journal article

Capper MS, Rehkämper M, Packman H, 2020, Rhenium-based complexes and in vivo testing: A brief history, ChemBioChem, Vol: 21, Pages: 2111-2115, ISSN: 1439-4227

The success of metal‐based anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32 / 78 cancer regimens, the use for metal‐based therapeutics has a clear role in cancer therapy. Despite this, metal‐based therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metal‐based therapeutics such as auranofin, a gold‐based drug candidate as well as ruthenium‐based candidates, NAMI‐A, NKP‐1339 and TLD‐1433. All are undergoing current clinical trials. Another class of complexes under study are rhenium‐based; such complexes have undergone extensive in vitro testing but only seven have displayed antitumor in vivo activity which is a necessary step before entering clinical trials. This present review will document, chronologically, the rhenium‐based drug candidates that have undergone in vivo testing and the outlook for such complexes.

Journal article

Capper MS, Enriquez Garcia A, Macia N, Lai B, Lin J-B, Nomura M, Alihosseinzadeh A, Ponnurangam S, Heyne B, Shemanko CS, Jalilehvand Fet al., 2020, Cytotoxicity, cellular localization and photophysical properties of Re(I) tricarbonyl complexes bound to cysteine and its derivatives, JBIC Journal of Biological Inorganic Chemistry, Vol: 25, Pages: 759-776, ISSN: 0949-8257

Journal article

Banerjee S, Capper MS, Clarkson GJ, Huang H, Sadler PJet al., 2019, Dual-action platinum(II) Schiff base complexes: Photocytotoxicity and cellular imaging, Polyhedron, Vol: 172, Pages: 157-166, ISSN: 0277-5387

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=01781990&limit=30&person=true